3538 completed, 1072 recruiting, 831 unknown, 670 terminated. 2142 Not applicable, 2031 Phase 2, 1146 Phase 1, 697 Phase 3, 229 Phase 4.
Follow Prostatic Diseases: new trials by email Literature Review of Prostatic Diseases trials Research Report on Prostatic Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PROstate Cancer Risk Calculator for ACTionable Clinical Decision-making in Nigeria (a) Training and (b) Supported risk assessment - Prostate Cancer, Risk Assessment | Not applicable | Not yet recruiting | Ahmadu Bello University | 89 | 2029-03-01 | 2026-07-29 |
| A Phase 1/2 Study of Personalized PSMA Radiopharmaceutical Therapy 177Lu-PSMA-I&T - escalating renal absorbed dose, 177Lu-PSMA-I&T - recommended phase 2 regime - Cancer, Prostate Cancer | Phase 1 / Phase 2 | Not yet recruiting | CHU de Quebec-Universite Laval | 500 | 2028-03-01 | 2025-03-30 |
| REGN21353 Alone or in Combination With Nezastomig for Metastatic Castration-Resistant Prostate Cancer in Adult Participants REGN21353, Nezastomig, Sarilumab Prophylaxis (Contingency) - Metastatic Castration-Resistant Prostate Cancer, mCRPC | Phase 1 / Phase 2 | Not yet recruiting | Regeneron Pharmaceuticals | 192 | 2027-06-28 | 2026-09-30 |
| Understanding the Role of MyCareGorithm as a Visual Digital Platforms in Cancer Treatment Education and Patient Comprehension of Oncology Treatment Plans Survey - Head and Neck Cancer, Prostate Cancer | Not applicable | Not yet recruiting | M.D. Anderson Cancer Center | 94 | 2027-03-01 | 2026-10-01 |
| Testing the Anti-cancer Drug DSP-5336 (Enzomenib) in Prostate Cancer Antiandrogen Therapy, Biopsy Procedure, Biospecimen Collection - Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 24 | 2027-02-26 | 2026-11-12 |
| Prostate Stereotactic Radiation and Radio-induced Lymphocyte Apoptosis for Predicting Late Toxicities in Prostate Cancer (PROSTERA) Radio-induced Lymphocyte Apoptosis (RILA) Assay, Stereotactic body radiotherapy (SBRT) - Prostate Cancer | Not applicable | Not yet recruiting | Clinique Sainte Clotilde | 220 | 2027-02-01 | 2026-10-26 |
| Analysis of the Performance of PSMA Emission Tomography in Patients With Prostate Cancer Treated With HIFU Nuclear imaging (PSMA PET) with intravenous injection of a radiotracer one year after treatment (focal therapy) - Prostate Cancer - Recurrent, Prostate Cancer (Diagnosis) | Phase 4 | Not yet recruiting | University Hospital, Toulouse | 30 | 2027-02-01 | 2026-11-05 |
| iCCARE Project #4: Grounded Theory Study of the Social Determinants of Migrant Health Factors Impacting Prostate Cancer Care and Survivorship Among Sub-Saharan African and Caribbean Immigrant Men Diagnosed With Prostate Cancer Interviews - Prostate Cancer | Not applicable | Not yet recruiting | M.D. Anderson Cancer Center | 40 | 2027-01-31 | 2026-10-06 |
| HRT-PC Trial: Hormone Recovery After Treatment for Prostate Cancer Trial. An Open-label Phase II Study of Clomiphene Citrate in Patients With Persistent Hypogonadism After ADT for Treatment of Localized Prostate Cancer Clomiphene Citrate 25mg - Prostate Cancer | Phase 2 | Not yet recruiting | University of Nebraska | 83 | 2027-01-31 | 2026-10-20 |
| Quality and Safety of Real-Time Brachytherapy Treatments: Clinical Implementation of a Multipoint Scintillation Detector for Treatment Monitoring Brachytherapy treatment monitoring using a plastic scintillation detector - Prostate Cancer, Gynecologic Cancers | Not applicable | Not yet recruiting | CISSS de Chaudière-Appalaches | 25 | 2027-01-15 | 2026-10-21 |
| Testing the Use of High Dose Testosterone Followed by Darolutamide Compared to the Usual Care for Patients With Metastatic Prostate Cancer Abiraterone Acetate, Biospecimen Collection, Bone Scan - Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 2 / Phase 3 | Not yet recruiting | ECOG-ACRIN Cancer Research Group | 432 | 2027-01-06 | 2026-10-01 |
| Veteran Peer Navigators to Promote Shared Decision Making for PSA Screening Veteran Peer Decision Coaching Session for PSA Screening - Prostate Cancer | Not applicable | Not yet recruiting | VA Office of Research and Development | 228 | 2027-01-04 | 2026-10-21 |
| ALSO-PERFORM Study. ALternating Stereotaxic Or PElvic Radiotherapy FOR Metachronic Metastatic Prostate Cancer Prostate Cancer | Not yet recruiting | Amsterdam UMC, location VUmc | 130 | 2027-01-01 | 2026-10-08 | |
| Pilot Feasibility Study of a Dyadic Culinary Nutrition Intervention Cooking Healthy - Engaging Families (CHEF), Control - Neoplams, Prostate Cancer (Adenocarcinoma) | Not applicable | Not yet recruiting | University of Arizona | 40 | 2027-01-01 | 2026-07-14 |
| Weekly Online CT or MR Adaptive Definitive SBRT for Regionally Metastatic Prostate Cancer weekly CT or MR online adaptive definitive SBRT - Prostate Cancer | Not applicable | Not yet recruiting | University of Zurich | 54 | 2027-01-01 | 2026-08-21 |
| Magnetic Resonance-Guided Stereotactic Body Radiation Therapy for the Treatment of Prostate Cancer Biopsy Procedure, Computed Tomography, Electronic Health Record Review - Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8 | Not applicable | Not yet recruiting | City of Hope Medical Center | 20 | 2027-01-01 | 2026-08-17 |
| Investigation of an Intelligent Centre-adaptive Multi-modal Fusion Framework (Cad- MMFF) to Overcome Unnecessary Prostate Biopsies and Optimize MRI Utilization Prostate Cancer (Diagnosis) | Not yet recruiting | Chinese University of Hong Kong | 400 | 2027-01-01 | 2026-10-22 | |
| ALT-100 Monoclonal Antibody (mAb) in Bone-Predominant Metastatic Androgen Pathway Modulation Resistant (APMR) Prostate Cancer -- The ALTAR-100 Trial ALT-100 - Prostate Cancer Metastatic to Bone | Phase 1 / Phase 2 | Not yet recruiting | University of Florida | 42 | 2027-01-01 | 2026-11-04 |
| Remote Screening and Navigation to Increase Trial Enrollment, INVITE Trial Electronic Health Record Review, Patient Navigation, Prescreen - Bladder Carcinoma, Prostate Carcinoma | Not applicable | Not yet recruiting | Fred Hutchinson Cancer Center | 50 | 2027-01-01 | 2026-11-06 |
| RELEASE Ph2 RT-310 BPH Study RT-310 PK, Placebo, RT-310 - Benign Prostatic Hyperplasia (BPH) | Phase 2 | Not yet recruiting | Resurge Therapeutics Inc. | 86 | 2027-01-01 | 2026-11-10 |
Showing 20 of 7347. Sign in to see all of them.
Prostatic Neoplasms (6463) · Prostatic Hyperplasia (812) · Breast Neoplasms (548) · Neoplasms (415) · Lung Neoplasms (259) · Neoplasm Metastasis (252) · Colorectal Neoplasms (247) · Ovarian Neoplasms (234) · Urinary Bladder Neoplasms (208) · Pancreatic Neoplasms (194) · Carcinoma, Non-Small-Cell Lung (169) · Lower Urinary Tract Symptoms (158) · Colonic Neoplasms (139) · Melanoma (127) · Stomach Neoplasms (127)
Genital Diseases (7341) · Urogenital Diseases (7338) · Male Urogenital Diseases (7328) · Genital Diseases, Male (7321) · Neoplasms by Site (6508) · Genital Neoplasms, Male (6477) · Urogenital Neoplasms (6471) · Neoplasms (6122) · Pathological Conditions, Signs and Symptoms (1006) · Female Urogenital Diseases (717) · Female Urogenital Diseases and Pregnancy Complications (717) · Skin and Connective Tissue Diseases (611) · Skin Diseases (606) · Breast Diseases (573)
Docetaxel (307) · Prednisone (253) · enzalutamide (218) · Leuprolide (189) · Abiraterone Acetate (182) · Radiotherapy (182) · Magnetic Resonance Spectroscopy (169) · bicalutamide (143) · Goserelin (140) · Androgen Antagonists (131) · Radiosurgery (113) · acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide (111) · apalutamide (99) · abiraterone (92) · Tamsulosin (89)
National Cancer Institute (NCI) (198) · Memorial Sloan Kettering Cancer Center (135) · M.D. Anderson Cancer Center (122) · University Health Network, Toronto (96) · Mayo Clinic (71) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (71) · AstraZeneca (70) · Jonsson Comprehensive Cancer Center (68) · University of California, San Francisco (60) · Novartis Pharmaceuticals (57) · Dana-Farber Cancer Institute (56) · GlaxoSmithKline (53) · Bayer (51) · Janssen Research & Development, LLC (49) · Chinese University of Hong Kong (48)
United States (3624) · Canada (720) · France (515) · China (475) · United Kingdom (473) · Italy (352) · Germany (329) · Spain (304) · Netherlands (270) · South Korea (253) · Australia (249) · Belgium (228) · Denmark (158) · Poland (152) · Sweden (143)
Rahul Aggarwal, MD (18) · Chi Fai NG, MD (16) · Mary-Ellen Taplin, MD (14)
PMID 34350976, PMID 24722180, PMID 33270906, PMID 41698328, PMID 33465252, PMID 36884035, PMID 38421243, PMID 38421252, PMID 22894553, PMID 25712310, PMID 25819287, PMID 27626136, PMID 29272162, PMID 32994091, PMID 38320143, PMID 22747660, PMID 25592642, PMID 25613154, PMID 26299520, PMID 27626365, PMID 37070660, PMID 40016438, PMID 20818327, PMID 21106711, PMID 21420124, PMID 22129214, PMID 22932804, PMID 24423462, PMID 24972732, PMID 25614256, PMID 25626035, PMID 25687533, PMID 25754526, PMID 26512712, PMID 27044935, PMID 27339115, PMID 29240541, PMID 29873008, PMID 30677455, PMID 31227373, PMID 31375469, PMID 31540791, PMID 32203306, PMID 32878613, PMID 34529005, PMID 35084544, PMID 35643841, PMID 35731340, PMID 36383907, PMID 36596347
2023 (42), 2017 (26), P30CA014089 (24), 2025 (23), P30CA033572 (22), 2016 (21), P30CA072720 (20), 2019 (19), U10CA031946 (18), 2008 (17), P30CA015704 (16), 2014 (15), P30CA016672 (15), P30CA022453 (15), P30CA012197 (13)